Roger Corbett AO to be appointed to the Board of HalcyGen

18-Oct-2010 - HalcyGen Pharmaceuticals Limited announced that Mr Roger Corbett AO is seeking shareholder approval to be elected as a Non Executive Director of the Company at the Annual General Meeting on 17th November 2010. Mr Corbett has unparalleled retail and corporate experience both in Australia and ...

Successful Outcome from European Clinical Pharmacokinetic Study Comparing SUBA-Itraconazole with Sporanox

HalcyGen to begin Marketing Authorisation Application for Regulators in Europe

04-Mar-2010 - HalcyGen Pharmaceuticals Limited announced that preliminary results from its UK-based pharmacokinetic study (PK) comparing a half-dose of anti-fungal drug SUBA-Itraconazole with Sporanox®, has shown clinical bioequivalence within EU guidelines. Following a pre-registration meeting with the ...

Halcygen to acquire wholly owned subsidiary of Hospira

28-Sep-2009 - HalcyGen Pharmaceuticals Limited has entered into a definitive agreement with Hospira Australia Pty Ltd, a wholly owned subsidiary of Hospira Inc., to acquire all the outstanding shares in Mayne Pharma International Pty Ltd (MPI) – one of the businesses Hospira purchased when it acquired Mayne ...

New potential application for SUBA-Itraconazole in oncology

Improved anti-fungal drug targets oncology market

12-Jun-2008 - HalcyGen Pharmaceuticals Limited can confirm that itraconazole, the active ingredient in HalcyGen's lead drug SUBA-Itraconazole, is a potent inhibitor of the proliferation of endothelial cells. These are the key cells involved in tumour-angiogenesis and related growth of tumours. This finding ...